Caliway Biopharmaceuticals (TWSE: 6919), a clinical-stage biopharmaceutical company advancing innovative small-molecule therapies in aesthetic medicine, metabolic diseases, and other unmet medical ...
CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a ...
Q4 2025 Earnings Call April 1, 2026 8:30 AM EDTCompany ParticipantsJoshua Blacher - Chief Financial OfficerChristopher Miglino ...
Management expects completion of VISTAS study enrollment for Volixibat in PSC in the third quarter of 2025, with data readout ...
Turbulence linked to the war in Iran and swings in valuations have yet to deter corporate deal-making as transactions in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results